Os therapies announces positive data for ost-her2 in the treatment of unresected osteosarcoma in dogs opening the potential for use as front-line therapy in humans

New york--(business wire)--os therapies (nyse-a: ostx) (“os therapies” or “the company”), a clinical-stage immunotherapy and antibody drug conjugate (adc) biopharmaceutical company, today announced positive data in the prevention or delay of amputation during the treatment of primary osteosarcoma for ost-her2 combined palliative radiation in dogs with unresected appendicular osteosarcoma. the treatment led to clinical and radiographic arrest of the primary tumor and prolonged time to metastasis.
OST Ratings Summary
OST Quant Ranking